Because CD30 is highly expressed on Hodgkin's lymphoma and anaplastic large cell lymphoma, it is a promising target for immunotherapy. The extracellular portion of CD30 is cleaved, releasing a form known as soluble CD30 ("sCD30"), which can reduce the effects of CD30-targeting agents by competitive binding. The antibody binds to the membrane-specific epitopes (Ep2) are located near the middle of the extracellular domain of CD30 that are missing on soluble CD30. Ligands that bind to these epitopes can be used to target cells with intact CD30 without competition from sCD30.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-144 | Anti-Human CD30 Recombinant Antibody (Iratumumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
There are currently no Customer reviews or questions for HPAB-0334-YC-F(E). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.